Physician profile
Gharoon Panahi
NPI 1912956053
$6,581.43
in general payments reported to CMS, 2019-2025
27 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $330 · 2021: $353 · 2022: $892 · 2023: $640 · 2024: $1,318 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,232.52 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,162.78 | 2019-2025 | Evenity, Prolia, Otezla |
| Mallinckrodt Hospital Products INC. | $681.67 | 2020-2025 | Acthar |
| Pfizer INC. | $583.71 | 2019-2025 | |
| Ucb, INC. | $427.03 | 2023-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $412.79 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $412.51 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $346.38 | 2019-2025 | Tymlos |
| Abbvie INC. | $214.40 | 2025 | |
| Lilly USA, LLC | $203.54 | 2019-2025 | Zepbound, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.95 | 2024-2025 | Ofev |
| Aurinia Pharma U.S., INC. | $110.86 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $102.34 | 2019-2022 | |
| Fidia Pharma USA INC. | $76.38 | 2019-2025 | Triluron, Hymovis |
| Scilex Pharmaceuticals INC. | $64.87 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $56.07 | 2019 | |
| Ani Pharmaceuticals, INC. | $54.41 | 2024-2025 | Purified Cortrophin Gel |
| Cumberland Pharmaceuticals, INC. | $51.59 | 2022 | |
| Kaleo, INC. | $46.15 | 2019 | |
| Alvogen INC | $43.68 | 2025 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $43.36 | 2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $39.60 | 2022 | |
| Genzyme Corporation | $24.08 | 2025 | |
| Emergent Biosolutions INC. | $23.19 | 2019 | |
| Depuy Synthes Sales INC. | $14.80 | 2023 | Monovisc, Orthovisc |
| Ultragenyx Pharmaceutical INC. | $13.08 | 2023 | Crysvita |
| Genentech USA, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gharoon Panahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.